|
End-of-day quote
Palestine Exchange
2026-08-19
|
5-day change | 1st Jan Change | ||
| 3.600 USD | +2.86% |
|
0.00% | +56.52% |
| 08-13 | Jerusalem Pharmaceuticals Co. Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
| 06-30 | Jerusalem Pharmaceuticals Announces Board Changes | CI |
| Market Cap | 130M 111M 104M 95.08M 178M 12.4B 181M 1.23B 479M 6.23B 487M 476M 20.6B | P/E 2024 |
13.7x | P/E 2025 | 8.13x |
|---|---|---|---|---|---|
| Enterprise Value | 119M 102M 95.14M 87.09M 163M 11.36B 166M 1.12B 438M 5.71B 446M 436M 18.87B | EV / Sales 2024 |
1.47x | EV / Sales 2025 | 1.47x |
| Free-Float |
35.74% | Yield 2024 |
2.09% | Yield 2025 | 3.26% |
| 1 day | +2.86% | ||
| Current month | -4.00% | ||
| 1 month | +0.84% | ||
| 3 months | -5.01% | ||
| 6 months | +55.51% | ||
| Current year | +56.52% |
| 1 week | 3.5 | 3.6 | |
| 1 month | 3.5 | 3.75 | |
| Current year | 2.28 | 4 | |
| 1 year | 1.9 | 4 | |
| 3 years | 1.74 | 4 | |
| 5 years | 1.32 | 4 | |
| 10 years | 0.8 | 4 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 2013-06-30 | |
Mohammed Natour
DFI | Director of Finance/CFO | - | 2020-02-29 |
Lina Masrouji
CTO | Chief Tech/Sci/R&D Officer | - | 1988-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 91 | - | |
Nidal Kamal
BRD | Director/Board Member | - | - |
| Director/Board Member | - | - |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +2.86% | 0.00% | +73.49% | +88.48% | 130M | ||
| -0.08% | -1.43% | +15.87% | +67.24% | 47.71B | ||
| -3.21% | +1.37% | +51.19% | +124.26% | 40.3B | ||
| -0.40% | -1.23% | -10.08% | +17.30% | 12.09B | ||
| +1.11% | -1.34% | +13.27% | +72.07% | 11.68B | ||
| +0.19% | +0.58% | +30.98% | +151.21% | 9.19B | ||
| -0.39% | -0.92% | +20.49% | +39.85% | 7.57B | ||
| -1.35% | +0.74% | +47.38% | -12.13% | 7.24B | ||
| -0.64% | -0.02% | +19.65% | +205.39% | 6.84B | ||
| -5.36% | -6.36% | -38.04% | +19.49% | 5.42B | ||
| Average | -0.73% | -1.14% | +22.42% | +77.31% | 14.82B | |
| Weighted average by Cap. | -1.14% | -0.57% | +24.12% | +83.63% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 39.82M 34.11M 31.92M 29.22M 54.83M 3.81B 55.56M 377M 147M 1.91B 150M 146M 6.33B | 48.95M 41.93M 39.23M 35.91M 67.39M 4.68B 68.28M 463M 181M 2.35B 184M 180M 7.78B |
| Net income | 5.04M 4.32M 4.04M 3.7M 6.94M 482M 7.03M 47.71M 18.6M 242M 18.92M 18.5M 801M | 10.18M 8.72M 8.16M 7.47M 14.02M 974M 14.21M 96.43M 37.6M 489M 38.24M 37.4M 1.62B |
| Net Debt | -10.32M -8.84M -8.27M -7.57M -14.21M -988M -14.4M -97.74M -38.12M -496M -38.76M -37.91M -1.64B | -10.9M -9.33M -8.73M -7.99M -15M -1.04B -15.2M -103M -40.24M -524M -40.92M -40.03M -1.73B |
Employees
595
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-08-19 | US$3.600 | +2.86% | 1,200 |
| 26-08-18 | US$3.500 | -2.78% | 5,437 |
| 26-08-17 | US$3.600 | 0.00% | 65 |
- Stock Market
- Stocks
- JPH Stock
Select your edition
All financial news and data tailored to specific country editions
















